Physician profile
Robert S Burress
NPI 1740287382
$832.28
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $237.90 | 2019 | |
| Genentech USA, INC. | $117.21 | 2019 | |
| Glaxosmithkline, LLC. | $100.87 | 2019 | |
| Genzyme Corporation | $79.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $73.69 | 2019 | |
| Optinose US, INC. | $69.13 | 2019 | |
| Alk-Abello, INC | $29.80 | 2019 | |
| Pharming Healthcare, INC. | $28.00 | 2019 | |
| Octapharma USA, INC. | $25.66 | 2019 | |
| Grifols USA, LLC | $20.95 | 2019 | |
| Kaleo, INC. | $19.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Burress listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.